middle.news
Paradigm Biopharma Boosts Cash by $6.3M to Power Osteoarthritis Trial
7:03pm on Monday 2nd of June, 2025 AEST
•
Pharmaceuticals
Read Story
Paradigm Biopharma Boosts Cash by $6.3M to Power Osteoarthritis Trial
7:03pm on Monday 2nd of June, 2025 AEST
Key Points
Received $6.3 million R&D Tax Incentive refund for FY24
Cash reserves now approximately $31 million
Advancing Phase 3 osteoarthritis clinical trial with recruitment planned for Q1 2025
Raised $16 million capital in December 2024
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PAR
OPEN ARTICLE